Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-755P (RNA, U6 small nuclear 755, pseudogene) is classified as a pseudogene in the human genome[1]. It is related by sequence to the canonical U6 small nuclear RNA (snRNA) family, particularly to U6 snRNA, which plays a key role in the spliceosome complex responsible for mRNA splicing in eukaryotic cells[5][3]. However, as a pseudogene, RNU6-755P does not encode a functional product and is not known to have a biological function, nor is it considered a therapeutic target[1]. Pseudogenes such as RNU6-755P typically arise from duplication or retrotransposition events and generally lack the capacity for protein or functional RNA product expression. While some pseudogenes can have regulatory roles or act as competing endogenous RNAs, there is no evidence that RNU6-755P is implicated in such functions or disease associations[1][4]. As a pseudogene, it is not druggable and does not serve as a clinical biomarker or therapeutic target. Note: The entry refers to a pseudogene, not a functional receptor, enzyme, or target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 755, pseudogene (RNU6-755P).